*Patients who experience recurrence can be retreated up to two times.1
†Median of 10 weeks (range of 6 to 24 weeks).1
‡Click here to see TARGET 3 Study Design.
Based on aggregated total of all prescribers as of October 2018.2
IBS-D = irritable bowel syndrome with diarrhea.
References: 1. XIFAXAN [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals. 2. IQVIA Xponent. October 2018.
Get information regarding XIFAXAN
Speak with a XIFAXAN representative
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.